As well studies have made evident that, the Malonyl-CoA produced in the lipogenesis pathway, suppresses the activity of CPT1B, inhibiting the transportation of fatty acids to the mitochondria by CPT1B, resulting in an accumulation of TGs and FAs in the hepatocytes and the subsequent development of NAFLD (Fig. 7). The gene discussed is CPT1B; the disease is metabolic dysfunction-associated steatotic liver disease.